Tris Patent-Cliff Exposure & CMS Drug Spending Portfolio

Tris (US): 8 reconciled FDA prescription therapies, $96.7M 2024 CMS Part D & Medicaid spend, and $1,985 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies8
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE Date2036-01-01
2024 CMS Total Public Spend$96.7M
2024 Medicare Part D Spend$61.6M
2024 Medicaid Spend$35.1M
California HCAI SB 17 FilingsSpecialty launch notice ($1,985 intro WAC)